8EZM image
Deposition Date 2022-11-01
Release Date 2023-08-16
Last Version Date 2024-10-23
Entry Detail
PDB ID:
8EZM
Keywords:
Title:
Pfs25 in complex with transmission-reducing antibody AS01-63
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.10 Å
R-Value Free:
0.23
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
C 1 2 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:25 kDa ookinete surface antigen
Chain IDs:A
Chain Length:182
Number of Molecules:1
Biological Source:Plasmodium falciparum
Polymer Type:polypeptide(L)
Molecule:Transmission-reducing antibody AS01-63, Single-chain Fv
Chain IDs:B (auth: H)
Chain Length:266
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
A human antibody epitope map of the malaria vaccine antigen Pfs25.
Npj Vaccines 8 108 108 (2023)
PMID: 37542029 DOI: 10.1038/s41541-023-00712-z

Abstact

Pfs25 is a leading antigen for a malaria transmission-blocking vaccine and shows moderate transmission-blocking activity and induction of rapidly decreasing antibody titers in clinical trials. A comprehensive definition of all transmission-reducing epitopes of Pfs25 will inform structure-guided design to enhance Pfs25-based vaccines, leading to potent transmission-blocking activity. Here, we compiled a detailed human antibody epitope map comprising epitope binning data and structures of multiple human monoclonal antibodies, including three new crystal structures of Pfs25 in complex with transmission-reducing antibodies from Malian volunteers immunized with Pfs25 conjugated to EPA and adjuvanted with AS01. These structures revealed additional epitopes in Pfs25 capable of reducing transmission and expanded this characterization to malaria-exposed humans. This work informs immunogen design to focus the antibody response to transmission-reducing epitopes of Pfs25, enabling development of more potent transmission-blocking vaccines for malaria.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback